Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.3K
The pathophysiology of pneumonia involves the following steps:
3.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extremes on the benign-malignant tumour spectrum: Distinct transcriptomic landscapes between two common canine perianal neoplasms based on the hallmarks of cancer.

PloS one·2026
Same author

The Chloride Channel Regulator, Calcium-Activated-1 Is Expressed in Synoviocytes and Articular Chondrocytes in Health and Disease.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·2026
Same author

Clade 2.3.4.4b H5N1 influenza A virus exhibits high infectivity in human respiratory tract models.

The Journal of infection·2026
Same author

Proteomic profiling of equine airway mucus reveals compositional changes in asthmatic phenotypes.

Scientific reports·2026
Same author

ET<sub>B</sub> receptor deficiency amplifies allergic airway inflammation and hyperresponsiveness.

ERJ open research·2026
Same author

Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models.

Cell stem cell·2026

Related Experiment Video

Updated: Feb 18, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K

Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia.

Birgitt Gutbier1, Xiaohui Jiang1, Kristina Dietert2

  • 1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Pulmonary Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Critical Care (London, England)
|November 15, 2017
PubMed
Summary

Vasculotide (VT) reduces lung injury in pneumonia by stabilizing pulmonary endothelium and decreasing permeability. This peptide mimics Angiopoietin-1, offering a potential new therapy for pneumonia-induced lung damage.

Keywords:
Acute lung injuryAngiopoietinsPneumococcal pneumoniaPneumolysinVasculotide

More Related Videos

Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay
08:43

Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

Published on: June 19, 2018

15.9K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K

Related Experiment Videos

Last Updated: Feb 18, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K
Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay
08:43

Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

Published on: June 19, 2018

15.9K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K

Area of Science:

  • Pulmonary Medicine
  • Vascular Biology
  • Pharmacology

Background:

  • Community-acquired pneumonia (CAP) causes significant global morbidity and mortality.
  • CAP can lead to life-threatening lung failure via pulmonary endothelial hyperpermeability.
  • Current treatments for acute lung injury are primarily supportive due to undetermined inflammation mechanisms.

Purpose of the Study:

  • To investigate the efficacy of Vasculotide (VT) in mitigating pneumonia-induced lung injury.
  • To determine if VT can reduce pulmonary endothelial hyperpermeability.
  • To explore VT's potential as a therapeutic agent for pneumonia.

Main Methods:

  • Analyzed VT binding and Tie2 phosphorylation using spectroscopy and ELISA.
  • Assessed lung endothelial cell integrity using immunofluorescence and impedance sensing.
  • Quantified pulmonary hyperpermeability in isolated mouse lungs and in vivo models of pneumonia.

Main Results:

  • VT demonstrated dose-dependent binding and Tie2 phosphorylation.
  • VT pretreatment protected endothelial cells and reduced permeability in isolated lungs stimulated with pneumolysin.
  • Therapeutic VT treatment in Streptococcus pneumoniae-infected mice significantly decreased pneumonia-induced hyperpermeability.

Conclusions:

  • Vasculotide (VT) enhances pulmonary endothelial stability and reduces lung permeability in experimental pneumonia models.
  • VT shows promise as a novel therapeutic strategy for reducing lung injury in pneumococcal pneumonia.
  • VT's mechanism involves promoting endothelial stability rather than modulating the inflammatory response.